You are asked to consult on a 76-year-old man admitted to the hospital with pneumonia and thrombocytopenia. Ten days before the current admission, he had undergone surgery to repair a small bowel obstruction. A preoperative platelet count had been normal. Following surgery, he received subcutaneous unfractionated heparin thromboprophylaxis until his discharge on post-operative day 5. In your differential diagnosis for the patient's thrombocytopenia, you consider heparin-induced thrombocytopenia (HIT) and wish to order laboratory testing. In addition to a polyspecific anti-PF4/heparin ELISA for the diagnosis of HIT, your laboratory has recently begun to offer an IgG-specific ELISA. You wonder which of these assays performs better in the diagnosis of HIT.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1182/asheducation-2009.1.250 | DOI Listing |
Bioanalysis
September 2024
Hematology Laboratory-Blood Bank, Aretaieio Hospital, School of Medicine, National & Kapodistrian University of Athens, Athens, Greece.
Heparin-induced thrombocytopenia (HIT) is a rare, life-threatening, immune-mediated adverse effect of heparin administration. This study compares frequently used laboratory assays in terms of their effectiveness in HIT diagnosis. Fifty patients with suspected HIT were tested by gel immunoassay and solid phase PF4/heparin antibody ELISA.
View Article and Find Full Text PDFGeorgian Med News
November 2023
College of Pharmacy, Al-Ayen University, Thi-Qar, Iraq.
The objective of this study is to investigate the impact of heparin-induced thrombocytopenia syndrome on individuals undergoing hemodialysis. Heparin-induced thrombocytopenia in hemodialysis patients (HD-HIT) is a condition believed to occur in hemodialysis patients who experience a sudden decrease in platelet count or unexplained blood clotting, particularly when there is evidence of thrombosis in the dialysis circuit despite adequate heparin dosage. HD-HIT is thought to be caused by a drug reaction and hyper immunoglobulin syndrome.
View Article and Find Full Text PDFJ Thromb Haemost
September 2023
Institute of Transfusion Medicine, University Medicine Greifswald, Greifswald, Germany. Electronic address:
Background: Rapid diagnosis and treatment has improved outcome of patients with vaccine-induced immune thrombocytopenia and thrombosis (VITT). However, after the acute episode, many questions on long-term management of VITT remained unanswered.
Objectives: To analyze, in patients with VITT, the long-term course of anti-platelet factor 4 (PF4) antibodies; clinical outcomes, including risk of recurrent thrombosis and/or thrombocytopenia; and the effects of new vaccinations.
Background: Hemorrhagic fever with renal syndrome (HFRS) induced by Hantaan virus infection and heparin-induced thrombocytopenia (HIT) are associated with symptoms such as thrombocytopenia and thrombosis. However, related molecules, such as anti-platelet factor 4 (PF4)/heparin antibodies, in patients with HFRS have not been evaluated.
Objectives: To test plasma levels of anti-PF4/heparin antibodies and study the possible role of these antibodies in HFRS pathogenesis.
Eur Heart J Open
September 2021
Division of Cardiovascular Medicine, Nouvel Hôpital Civil, Strasbourg University Hospital, 1 place de l'Hôpital, Strasbourg 67000, France.
Vaccine-induced immune thrombotic thrombocytopenia (VITT) (also termed thrombosis with thrombocytopenia syndrome or vaccine-induced thrombotic thrombocytopenia or vaccine-induced immune thrombocytopenia) is characterized by (i) venous or arterial thrombosis; (ii) mild-to-severe thrombocytopenia; (iii) positive antiplatelet factor 4 (PF4)-polyanion antibodies or anti-PF4-heparin antibodies detected by the HIT (heparin-induced thrombocytopenia) ELISA; (iv) occurring 5-30 days after ChAdOx1 nCoV-19 (AstraZeneca) or Ad26.COV2.S (Johnson & Johnson/Janssen) vaccination.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!